Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin
Swiss Medical Weekly · 2024
DOI: 10.57187/s.3632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Verena Gotta und 10 weiteren Autor:innen. Beteiligte Einrichtung: SwissPedDose/SwissPedNet collaboration expert team, Zürich/Basel/Lausanne, Switzerland. Hauptthemen laut MEDLINE: Amikacin, Neonatology. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND AND AIMS: Pharmacometric in silico approaches are frequently applied to guide decisions concerning dosage regimes during the development of new medicines. We aimed to demonstrate how such pharmacometric modelling and simulation can provide a scientific rationale for optimising drug doses in the context of the Swiss national dose standardisation project in paediatrics using amikacin as a case study. METHODS: Amikacin neonatal dosage is stratified by post-menstrual age (PMA) and post-natal age (PNA) in Switzerland and many other countries. Clinical concerns have been raised for the subpopulation of neonates with a post-menstrual age of 30–35 weeks and a post-natal age of 0–14 days (“subpopulation of clinical concern”), as potentially oto-/nephrotoxic trough concentrations (Ctrough >5 mg/l) were observed with a once-daily dose of 15 mg/kg. We applied a two-compartmental population pharmacokinetic model (amikacin clearance depending on birth weight and post-natal age) to real-world demographic data from 1563 neonates receiving anti-infectives (median birth weight 2.3 kg, median post-natal age six days) and performed pharmacometric dose-exposure simulations to identify extended dosing intervals that would ensure non-toxic Ctrough (Ctrough
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- SwissPedDose/SwissPedNet collaboration expert team, Zürich/Basel/Lausanne, Switzerland.
- Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland.
- Pediatric Clinical Pharmacy, University of Basel Children's Hospital, Basel Switzerland.
- Paediatric Research Centre and Paediatric Infectious Diseases and Vaccinology Division, University of Basel Children's Hospital, Basel, Switzerland.
- Centre for Neonatal and Paediatric Infection, St George's University, London, United Kingdom.
- Division of Infectious Diseaeses, University Children's Hospital Zurich, Zurich, Switzerland.
Zitieren
APA
Gotta, V., Bielicki, J. A., Paioni, P., Csajka, C., Bräm, D. S., Berger, C., Giger, E., Buettcher, M., Posfay-Barbe, K. M., Van den Anker, J., & Pfister, M. (2024). Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin. Swiss Medical Weekly. https://doi.org/10.57187/s.3632
Vancouver
Gotta V, Bielicki JA, Paioni P, Csajka C, Bräm DS, Berger C, et al. Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin. Swiss Medical Weekly. 2024. doi:10.57187/s.3632
BibTeX
@article{Gotta2024,
author = {Gotta, Verena and Bielicki, Julia Anna and Paioni, Paolo and Csajka, Chantal and Bräm, Dominic Stefan and Berger, Christoph and Giger, Elisabeth and Buettcher, Michael and Posfay-Barbe, Klara M and Van den Anker, John and Pfister, Marc},
title = {Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin},
journal = {Swiss Medical Weekly},
year = {2024},
doi = {10.57187/s.3632}
}
EUVIMED